Forte Biosciences
FBRX
52 hedge funds and large institutions have $6.83M invested in Forte Biosciences in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 7 increasing their positions, 22 reducing their positions, and 9 closing their positions.
2,500% more call options, than puts
Call options by funds: $104K | Put options by funds: $4K
0% more funds holding
Funds holding: 52 → 52 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
0.4% less ownership
Funds ownership: 1.46% → 1.07% (-0.4%)
46% less capital invested
Capital invested by funds: $12.6M → $6.83M (-$5.8M)
68% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$287K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$131K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$77.9K |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$60.6K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$53.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.02M |
| 2 |
Millennium Management
New York
|
-$601K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$459K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$292K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$161K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SC
51
Sculptor Capital
New York
| – | -$30K | -556 | Closed |
|
52
Squarepoint
New York
| – | -$28K | -525 | Closed |
|
|
AWM
53
Aries Wealth Management
Portland,
Maine
| – | -$28K | -520 | Closed |
|
|
EW
54
Evoke Wealth
Los Angeles,
California
| – | -$2K | -34 | Closed |
|
55
Fidelity Investments
Boston,
Massachusetts
| – | +$492 | +13 | New |
|
|
CAL
56
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$530 | +14 | New |
|
FBRX Hedge Fund Activity: Q1 2022 in Review
52 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q1 2022, worth a combined $6.83M — down 46% from $12.6M a quarter earlier.
Fund positioning in FBRX was balanced in Q1 2022: 9 funds opened new positions, 9 closed out, 7 added to existing stakes and 22 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $287K. The largest seller was Morgan Stanley, cutting an estimated $1.02M.
- 52 institutional investors held Forte Biosciences (FBRX) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $6.83M of Forte Biosciences stock for Q1 2022, down 46% quarter-over-quarter.
- 9 funds opened new Forte Biosciences positions in Q1 2022 and 9 closed out, a net change of 0 holders.
- The largest Forte Biosciences buyer in Q1 2022 was Renaissance Technologies, an estimated $287K added.
- The largest Forte Biosciences seller in Q1 2022 was Morgan Stanley, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2022.